human plasma
Recently Published Documents





2022 ◽  
Chetan Bhadaliya ◽  
Bala Krishna Panigrahy ◽  
Dipanjan Goswami ◽  
Sovan Maiti ◽  
Sanjay Jagannath Gurule ◽  

Biomedicines ◽  
2022 ◽  
Vol 10 (1) ◽  
pp. 162
Nicolai Bjødstrup Palstrøm ◽  
Rune Matthiesen ◽  
Lars Melholt Rasmussen ◽  
Hans Christian Beck

The human plasma proteome mirrors the physiological state of the cardiovascular system, a fact that has been used to analyze plasma biomarkers in routine analysis for the diagnosis and monitoring of cardiovascular diseases for decades. These biomarkers address, however, only a very limited subset of cardiovascular diseases, such as acute myocardial infarct or acute deep vein thrombosis, and clinical plasma biomarkers for the diagnosis and stratification cardiovascular diseases that are growing in incidence, such as heart failure and abdominal aortic aneurysm, do not exist and are urgently needed. The discovery of novel biomarkers in plasma has been hindered by the complexity of the human plasma proteome that again transforms into an extreme analytical complexity when it comes to the discovery of novel plasma biomarkers. This complexity is, however, addressed by recent achievements in technologies for analyzing the human plasma proteome, thereby facilitating the possibility for novel biomarker discoveries. The aims of this article is to provide an overview of the recent achievements in technologies for proteomic analysis of the human plasma proteome and their applications in cardiovascular medicine.

Bioanalysis ◽  
2022 ◽  
Inas A Abdallah ◽  
Sherin F Hammad ◽  
Alaa Bedair ◽  
Ahmed H Elshafeey ◽  
Fotouh R Mansour

Background: Favipiravir is an antiviral drug that was recently approved for the management of COVID-19 infection. Aim: This work aimed to develop a new method, using sugaring-out induced homogeneous liquid–liquid microextraction followed by HPLC/UV for the determination of favipiravir in human plasma. Materials & methods: The optimum extraction conditions were attained using 500 μl of tetrahydrofuran as an extractant and 1400 mg of fructose as a phase-separating agent. Results: The developed method was validated according to the US FDA bioanalytical guidelines and was found linear in the range of 25-80,000 ng/ml with a correlation coefficient of 0.999. Conclusion: These results showed that the developed method was simple, easy, valid and adequately sensitive for determination of favipiravir in plasma for bioequivalence studies.

Sign in / Sign up

Export Citation Format

Share Document